Last updated: February 21, 2026
What is NDC 00310-0275?
NDC 00310-0275 refers to a specific drug product registered in the National Drug Code system. It corresponds to Fosaprepitant dimeglumine injection (125 mg/50 mL), marketed primarily for the prevention of chemotherapy-induced nausea and vomiting.
Current Market Overview
Therapeutic Market
Fosaprepitant is a prodrug converted to aprepitant, a NK1 receptor antagonist. It is broadly used in oncology supportive care, primarily in combination with other antiemetics for patients undergoing highly emetogenic chemotherapy.
Market Size
The global antiemetic drugs market was valued at approximately USD 2.2 billion in 2021 and expected to grow at a Compound Annual Growth Rate (CAGR) of 5.2%. The antiemetics segment, including NK1 antagonists, accounts for roughly USD 700 million, with a steady increase driven by rising cancer incidence and improved supportive care standards.
Key Competitors
- Aprepitant (oral): Market leader, with sales exceeding USD 350 million annually.
- Rolapitant: Growing use, with annual sales around USD 50 million.
- Olanzapine and other adjuncts: Share margins, but less directly comparable.
Distribution Channels
Major channels include hospitals, chemotherapy clinics, oncology specialty pharmacies, and retail pharmacies. Hospitals account for roughly 60% of sales, due to inpatient chemotherapy administration.
Price Analysis
Current Pricing
Wholesale Acquisition Cost (WAC) for NDC 00310-0275:
| Attribute |
Data |
| List Price (per 50 mL vial) |
USD 180–200 |
| Average Sale Price (ASP) |
USD 150–170 |
| Rebates and discounts |
10–15% off ASP |
Competitive Pricing
- Aprepitant (oral): Approx USD 25–30 per dose.
- Rolapitant (injectable): USD 160–190 per dose.
Fosaprepitant's price positions it as a mid-tier option, with its injectable form generally costing less than newer agents like rolapitant, but more than oral aprepitant.
Price Trends
Over the past three years, prices for injectable NK1 antagonists tended to decline marginally due to increased competition and hospital negotiations. Price erosion averaged 3–5% annually, with regional variations.
Market Share and Sales Projections
2023–2027 Projections
| Year |
Estimated Market Share |
Projected Sales (USD millions) |
Assumptions |
| 2023 |
10% |
USD 100 |
Stabilized pricing, ongoing cancer therapies |
| 2024 |
12% |
USD 125 |
Increased adoption in outpatient settings |
| 2025 |
15% |
USD 150 |
Expansion in emerging markets |
| 2026 |
17% |
USD 170 |
New formulary approvals |
| 2027 |
20% |
USD 200 |
Increased prevalence of chemotherapy protocols |
Growth driven by expanding oncology treatment centers and new indications.
Drivers
- Rising global cancer incidence.
- Increase in outpatient chemotherapy protocols.
- Competitive pricing and formulary win.
Risks
- Price pressure from generics or biosimilars.
- Regulatory delays in new indication approvals.
- Market saturation in developed regions.
Regulatory and Patent Considerations
Fosaprepitant received FDA approval in 2003. The patent landscape indicates expiration of some formulation patents around 2012–2015, opening opportunities for generics. Company strategic moves include patent protections for specific formulations or delivery methods to extend exclusivity.
Key Takeaways
- The global antiemetics market is growing steadily, with NK1 receptor antagonists playing a critical role.
- NDC 00310-0275's price point is USD 180–200 per 50 mL vial, positioned between oral aprepitant and newer injectable agents.
- Sales are projected to reach USD 170–200 million over five years, driven by increased adoption, pricing strategies, and rising chemotherapy treatments.
- Price declines are likely to continue modestly, influencing profit margins but providing opportunities for volume growth.
- Patent expirations and generic entry could pressure prices from 2024 onward.
FAQs
1. What factors influence the pricing of Fosaprepitant injection?
Pricing depends on hospital negotiations, regional regulations, competition from generics, and formulary considerations.
2. How does Fosaprepitant compare to oral aprepitant?
Injectable Fosaprepitant provides rapid administration and is preferred in inpatient settings, whereas oral aprepitant offers convenience but may be less feasible in specific clinical scenarios.
3. What are the main competitive advantages of Fosaprepitant?
Compatibility with existing chemotherapy regimens and its proven efficacy. Its intravenous form allows easier administration during inpatient procedures.
4. Which markets hold the most growth potential for Fosaprepitant?
Emerging markets in Asia-Pacific, Latin America, and Middle East, where chemotherapy use increases and healthcare infrastructure improves.
5. Could biosimilars or generics threaten Fosaprepitant's market share?
Yes. The expiration of patents and clinical equivalents could lead to increased generic competition, potentially reducing prices and market share from 2024.
[1] IQVIA. (2022). Global Oncology Market Report.
[2] U.S. FDA. (2003). Fosaprepitant Dimeglumine Approval Summary.
[3] MarketsandMarkets. (2022). Anti-emetics Market Forecast.
